Newsletter

Healthcare Stocks

Zelira Therapeutics (ASX:ZLD) A 170% Surge Backed by Smart, Non-Dilutive Funding

External Validation Sends Shares Flying Zelira Therapeutics shares surged as much as 172% intraday, before settling around 73.5 cents, following a major funding announcement that the market clearly interpreted as far more than just another capital raise. The company announced that its HOPE 1 special purpose vehicle had secured approximately US$33 million in committed capital from…

ByCharlie YouldenJanuary 16, 2026

5 ASX Healthcare Companies with Game Changing Milestones in 2026!

2026 is set to be a big year for several ASX Healthcare Companies, especially companies in the pre-commercialisation stage. The two keys to get drugs or devices to market are to pass clinical trials and obtain regulatory approval. This article takes a look at 5 of the most exciting of those companies. What are the Best…

ByNick SundichJanuary 15, 2026

Singular Health (ASX:SHG) Gains FDA Clearance for Cloud Imaging Platform: Is This MedTech a Buy Now?

Singular Health secures FDA clearance for US rollout Singular Health Group (ASX: SHG) grabbed investor attention on Tuesday after the company announced FDA 510(k) clearance for its 3DICOM MD Cloud platform. Shares surged as high as A$0.30 in early trade, representing a 15% intraday gain, before profit-taking pulled the stock back to close at A$0.26.…

ByUjjwal MaheshwariJanuary 14, 2026

Telix Pharmaceuticals (ASX:TLX) Through the Commercialisation Chasm

The Market Lost Patience, the Strategy Did Not Telix Pharmaceuticals (ASX:TLX) is one of the more compelling examples of a biotech company pushing through the commercialisation chasm, often the most difficult phase in the sector’s lifecycle. This is the point where companies transition from deep, equity-funded cash burn into sustainable revenue generation, and many fail…

ByCharlie YouldenJanuary 13, 2026

EBR Systems (ASX:EBR) Surges 7.6% on Q4 Momentum: Time to Buy Before Full US Launch?

EBR Systems Gains Momentum Ahead of 2026 US Launch EBR Systems (ASX: EBR) is building serious momentum as it moves closer to a full US commercial launch in 2026. Shares jumped 7.6 per cent on Monday to AUD 1.06, up from a previous close of AUD 0.98, as investors responded to strong Q4 adoption numbers.…

ByUjjwal MaheshwariJanuary 13, 2026

Imricor Medical (ASX:IMR) FDA Approval Ignites Shares, but the Real Test Starts Now

FDA Approval Is a Big Win, Not the Finish Line Imricor Medical (ASX:IMR) received FDA clearance for its Vision-MR diagnostic catheter, marking the company’s first regulatory approval in the US and a significant milestone in its commercial journey. This approval enables Imricor to begin commercial rollout of the catheter, and the market responded positively, with…

ByCharlie YouldenJanuary 12, 2026

Mesoblast (ASX:MSB) Delivers 60% Jump in Ryoncil Sales, Strengthening Commercial Momentum

Mesoblast Lifts on Ryoncil Growth Mesoblast (ASX:MSB) delivered a very strong performance this morning following a positive guidance update for Ryoncil, its cell-based therapy and the only FDA approved treatment for steroid refractory acute graft versus host disease. This is a serious and often life-threatening condition with limited treatment options, which helps explain the growing…

ByCharlie YouldenJanuary 9, 2026

Cochlear (ASX:COH) is still a long term growth story you should listen to

Cochlear is one of few stocks that has created immense shareholder value and has also greatly improved the lives of its users. Yes, this can be said with respect to many ASX health stocks, but this one can hang its hat on its societal impacts more than most other companies. What are the Best ASX Stocks…

ByNick SundichJanuary 9, 2026

Ansell (ASX:ANN) Drops 6% on CEO Exit: Is This a Buying Opportunity?

Is Ansell's CEO Change a Hidden Opportunity for Investors? Ansell (ASX: ANN) fell over 6% on Thursday after announcing that CEO Neil Salmon will retire, with the stock dropping to its lowest level in three months. Shares closed at A$33.38, down from A$35.58 the previous day. The news caught some investors off guard, triggering a…

ByUjjwal MaheshwariJanuary 9, 2026

Novo Nordisk (CPH: NOVO-B): It’s not all smooth sailing for the US$180bn company behind obesity drug Ozempic

Not many 100-year old healthcare stocks see a sudden 30% jump in sales in one year and become the largest capitalised company on their entire continent but Novo Nordisk (CPH: NOVO-B) is one such stock that did just that. Its a Danish drug maker that is behind weight loss drugs Ozempic and Wegovy. For much of…

ByNick SundichJanuary 8, 2026

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Zelira Therapeutics (ASX:ZLD) A 170% Surge Backed by Smart, Non-Dilutive Funding

5 ASX Healthcare Companies with Game Changing Milestones in 2026!

Singular Health (ASX:SHG) Gains FDA Clearance for Cloud Imaging Platform: Is This MedTech a Buy Now?

Telix Pharmaceuticals (ASX:TLX) Through the Commercialisation Chasm

EBR Systems (ASX:EBR) Surges 7.6% on Q4 Momentum: Time to Buy Before Full US Launch?

Imricor Medical (ASX:IMR) FDA Approval Ignites Shares, but the Real Test Starts Now

Mesoblast (ASX:MSB) Delivers 60% Jump in Ryoncil Sales, Strengthening Commercial Momentum

Cochlear (ASX:COH) is still a long term growth story you should listen to

Ansell (ASX:ANN) Drops 6% on CEO Exit: Is This a Buying Opportunity?

Novo Nordisk (CPH: NOVO-B): It’s not all smooth sailing for the US$180bn company behind obesity drug Ozempic

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Stocks in Spotlight

Add Your Heading Text Here